The Effects of Imeglimin on Muscle Strength in Patients with Type 2 Diabetes: A Prospective Cohort Study.

IF 3.8 3区医学 Q2 Medicine

Diabetes Therapy Pub Date : 2024-11-01 Epub Date: 2024-09-09 DOI:10.1007/s13300-024-01639-x

Takeshi Oyanagi, Shin Kawanabe, Hidekazu Tsukiyama, Ami Nishine, Yuta Nakamura, Tomoko Nakagawa, Mayuko Kanou, Juri Kubota, Shingo Tsunemi, Kenichi Yokota, Masakatsu Sone

{"title":"The Effects of Imeglimin on Muscle Strength in Patients with Type 2 Diabetes: A Prospective Cohort Study.","authors":"Takeshi Oyanagi, Shin Kawanabe, Hidekazu Tsukiyama, Ami Nishine, Yuta Nakamura, Tomoko Nakagawa, Mayuko Kanou, Juri Kubota, Shingo Tsunemi, Kenichi Yokota, Masakatsu Sone","doi":"10.1007/s13300-024-01639-x","DOIUrl":null,"url":null,"abstract":"Introduction: A bidirectional relationship has been observed between type 2 diabetes mellitus and sarcopenia, especially among older adults. While previous studies have reported that imeglimin improves mitochondrial function, they have not assessed its effects on muscle strength in patients with type 2 diabetes. Therefore, we aimed to investigate the effects of imeglimin on muscle strength in patients with type 2 diabetes.Methods: In this prospective cohort study, we recruited consenting patients with type 2 diabetes (20-75 years). Changes in lean body mass (LBM), fat mass, quadriceps muscle strength, and grip strength from baseline (week 0) to week 24 were evaluated and compared between patients treated with imeglimin therapy (group I) and those who did not take imeglimin (controls, group C).Results: We recruited 27 patients treated with imeglimin (group I) and 29 controls (group C), and 50 of them completed the study (group I: n = 23; group C: n = 27). The change in LBM, total body fat mass, or skeletal muscle index from baseline to week 24 did not differ significantly between the two groups. However, group I exhibited a significantly higher percent change in quadriceps knee extension strength from baseline to week 24 than group C (13 ± 19% and 2.1 ± 14%, p = 0.022). Conversely, the difference in percent change in grip strength was not significant. Multivariable analysis showed that imeglimin use was significantly associated with a percent change in quadriceps knee extension strength, independent of age, sex, body mass index, and skeletal mass index (β = 0.325, p = 0.0014).Conclusions: Imeglimin positively affected muscle strength in patients with type 2 diabetes without altering LBM. Therefore, imeglimin exerts a unique effect on skeletal muscles in humans. Further randomized controlled trials are needed to validate these findings.Trial registration: This research was registered in the University Hospital Medical Information Network (UMIN, UMIN000054715).","PeriodicalId":11192,"journal":{"name":"Diabetes Therapy","volume":" ","pages":"2323-2336"},"PeriodicalIF":3.8000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11466917/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13300-024-01639-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/9 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: A bidirectional relationship has been observed between type 2 diabetes mellitus and sarcopenia, especially among older adults. While previous studies have reported that imeglimin improves mitochondrial function, they have not assessed its effects on muscle strength in patients with type 2 diabetes. Therefore, we aimed to investigate the effects of imeglimin on muscle strength in patients with type 2 diabetes.

Methods: In this prospective cohort study, we recruited consenting patients with type 2 diabetes (20-75 years). Changes in lean body mass (LBM), fat mass, quadriceps muscle strength, and grip strength from baseline (week 0) to week 24 were evaluated and compared between patients treated with imeglimin therapy (group I) and those who did not take imeglimin (controls, group C).

Results: We recruited 27 patients treated with imeglimin (group I) and 29 controls (group C), and 50 of them completed the study (group I: n = 23; group C: n = 27). The change in LBM, total body fat mass, or skeletal muscle index from baseline to week 24 did not differ significantly between the two groups. However, group I exhibited a significantly higher percent change in quadriceps knee extension strength from baseline to week 24 than group C (13 ± 19% and 2.1 ± 14%, p = 0.022). Conversely, the difference in percent change in grip strength was not significant. Multivariable analysis showed that imeglimin use was significantly associated with a percent change in quadriceps knee extension strength, independent of age, sex, body mass index, and skeletal mass index (β = 0.325, p = 0.0014).

Conclusions: Imeglimin positively affected muscle strength in patients with type 2 diabetes without altering LBM. Therefore, imeglimin exerts a unique effect on skeletal muscles in humans. Further randomized controlled trials are needed to validate these findings.

Trial registration: This research was registered in the University Hospital Medical Information Network (UMIN, UMIN000054715).

Abstract Image

查看原文本刊更多论文

Imeglimin 对 2 型糖尿病患者肌力的影响：前瞻性队列研究

导言：据观察，2 型糖尿病与肌肉疏松症之间存在双向关系，尤其是在老年人中。虽然之前的研究报告称伊迈格列明可改善线粒体功能，但并未评估其对 2 型糖尿病患者肌肉力量的影响。因此，我们旨在研究伊迈格列明对 2 型糖尿病患者肌肉力量的影响：在这项前瞻性队列研究中，我们招募了征得同意的 2 型糖尿病患者（20-75 岁）。评估并比较了接受伊迈格列明治疗的患者（I组）和未接受伊迈格列明治疗的患者（对照组，C组）从基线（第0周）到第24周的瘦体重（LBM）、脂肪量、股四头肌肌力和握力的变化：我们招募了 27 名接受伊麦格列明治疗的患者（I 组）和 29 名对照组（C 组），其中 50 人完成了研究（I 组：n = 23；C 组：n = 27）。从基线到第 24 周，两组患者的 LBM、全身脂肪量或骨骼肌指数的变化没有显著差异。然而，从基线到第 24 周，I 组股四头肌伸膝力量的百分比变化明显高于 C 组（13 ± 19% 和 2.1 ± 14%，p = 0.022）。相反，握力的百分比变化差异并不显著。多变量分析表明，使用伊麦格列明与股四头肌伸膝力量的百分比变化有显著相关性，不受年龄、性别、体重指数和骨骼质量指数的影响（β = 0.325，p = 0.0014）：伊麦格列明对 2 型糖尿病患者的肌肉力量有积极影响，但不改变 LBM。因此，伊麦格列明对人体骨骼肌具有独特的作用。需要进一步的随机对照试验来验证这些发现：本研究已在大学医院医学信息网（UMIN，UMIN000054715）注册。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes Therapy Medicine-Endocrinology, Diabetes and Metabolism

CiteScore

6.90

自引率

7.90%

发文量

130

审稿时长

6 weeks

期刊介绍： Diabetes Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all areas of diabetes. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Diabetes Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.